<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350230</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2017-05</org_study_id>
    <nct_id>NCT03350230</nct_id>
  </id_info>
  <brief_title>Embryonic Ploidy Status in the Oncofertility Population</brief_title>
  <official_title>Embryonic Ploidy Status in the Oncofertility Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      looking at aneuploidy rates in embryos from patients who are going to or have undergone
      treatment for a malignancy with gonadotoxic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves oncofertility patients--individuals who are undergoing or have undergone
      therapy for a malignancy--who are interested in pursuing or preserving fertility. In
      particular, it investigates chromosomal abnormalities or aneuploidy in the embryos of those
      individuals as compared to the general infertility population. Embryonic aneuploidy is
      largely due to reproductive senescence. As such the investigators will discuss oncofertility
      prevalence and treatment as well as reproductive senescence and assessment of embryonic
      aneuploidy. The study will seek to determine if there are changes in embryonic aneuploidy
      rates in oncofertility patients that differ from simple age related risks.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>embryonic aneuploidy rates</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate the incidence of embryonic aneuploidy among oncofertility patients compared to the general infertility population</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Oncology</condition>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>oncofertility patients</arm_group_label>
    <description>oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood specimens and buccal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        oncofertility patient undergoing controlled ovarian hyperstimulation and embryo
        cryopreservation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Present or past oncologic diagnosis requiring potentially gonadotoxic treatment

        Exclusion Criteria:

          1. Oocyte banking

          2. Use of oocyte donation

          3. Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation

          4. Single gene disorder requiring more detailed embryo genetic analysis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Franasiak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Medicine Associates of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

